N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
N/A N=73 Drug Therapy to Treat Minor Depression
Depression
Primary: Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) — -11.47; -9.35; -10.49 units on a scale
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 2 N=128 Clinical Study to Test a New Drug to Treat Major Depression
Depressive Disorder, Major
Primary: Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score. — -6.5; -5.6…
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
N/A N=48 Standardized Versus Tailored Implementation of Measurement Based Care for Depression
Depression
Primary: Patient Health Questionnaire — 18.04; 16.77; 12.15; 13.09 score on a scale
Phase 4 N=53 Effects of Treatment on Decision-making in Major Depression
Major Depressive Disorder · Healthy Controls
Primary: Money Earned — 23.2; 25.0; 20.5; 21.9 US Dollars
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
Phase 4 N=339 A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
Major Depressive Disorder
Primary: Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 36.1; 36.0; -20.1; -19.9 units on a scale — p=0.88
N/A N=11 Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
MDD
Primary: Depression Severity Changes Scored From Patient Health Questionnaire (PHQ9) — 5; 6.71; 8.14; 9.14 score on a scale
Phase 3 N=598 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…
Phase 2 N=360 A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12; -12; -12 score on a scale
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
Phase 3 N=615 A Study of MD-120 in Patients With Depression
Major Depressive Disorder
Primary: Changes in Total MADRS Score From the Baseline to Week 8 Visit During the Treatment Period — -10.4; -11.1; -11.9 Score on a scale — p=0.509
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
N/A N=12,909 Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
Major Depressive Disorder · Major Depressive Episode
Primary: Major Depressive Disorder (MDD) Composite: Positive Patient Health Questionnaire-9 (PHQ-9; Universal Arm) or MDD Concern Prompting Student Assistance Program (SAP)…
Phase 2 N=120 A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D-17) Scores — 20.1; 19.9; 14.7; 15.6 points
Phase 2 N=150 A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for…
Phase 4 N=16 Identifying and Treating Depression in Hemodialysis Patients
Depression · Hemodialysis-Induced Symptom
Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
N/A N=38 Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial
Depression, Unipolar
Primary: Intent-to-Treat Analysis of Adjusted Mean Beck Depression Inventory-II Scores Over Intervention Period — 20.98; 19.92; 15.15; 13.06 points on a scale — p=0.034
N/A N=30 Intensive tDCS for MDD: Feasibility Study
Major Depressive Disorder
Primary: Change in Depressive Symptoms Measured by the Patient Health Questionnaire (PHQ-9) — 21; 31.5 percentage of change
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001